AI Article Synopsis
- - A patient experienced decreased vision while on topiramate (TPM) for epilepsy, leading to an ophthalmological exam that indicated maculopathy.
- - After discontinuing TPM, the patient's vision did not show significant improvement over six months.
- - The authors speculate that TPM may have caused maculopathy, similar to how vigabatrin can lead to retinal toxicity and lasting visual issues.
Article Abstract
The case of a patient who developed decreased vision while taking topiramate (TPM) for symptomatic epilepsy is described. Ophthalmological examination revealed findings suggestive of maculopathy. TPM was discontinued; however, vision failed to improve significantly over 6 months of follow-up. We hypothesize that the patient's maculopathy was induced by TPM. TPM, like vigabatrin, may exert retinal toxicity causing persistent visual impairment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yebeh.2008.12.015 | DOI Listing |
Publication Analysis
Top Keywords
presumed topiramate-induced
4
topiramate-induced maculopathy
4
maculopathy case
4
case patient
4
patient developed
4
developed decreased
4
decreased vision
4
vision topiramate
4
tpm
4
topiramate tpm
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!